Rare and ultra-rare cancers affect around 20,000 people in the United States alone, according to Foundation Medicine, Inc. Immunotherapy research in some of the more common cancers and the identification of biomarkers that can predict patient responses is opening this new approach to cancer treatment up to patients whose cancers currently receive little direct attention.

Cancer is not “one-size-fits-all” and neither are its treatments, especially when it comes to immunotherapy. Learn how CRI is helping more people overcome cancer.